A Test in Context: Neprilysin: Function, Inhibition, and Biomarker

Journal of the American College of Cardiology

Volumn 68, Issue 6, 2016, Pages 639-653

  Bayes Genis, Antoni ^a,b   Barallat, Jaume ^a   Richards, A Mark ^c,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

amyloid beta peptides; angiotensin receptor neprilysin inhibitor; endopeptidases; heart failure; natriuretic peptides; renin angiotensin system

Indexed keywords

BIOLOGICAL MARKER; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST;

ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SYNTHESIS; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; PHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BIOMARKERS; HEART FAILURE; HUMANS; NEPRILYSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84992053005     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.04.060     Document Type: Review

References (99)

1. 1 McMurray, J.J.V., Packer, M., Desai, A.S., et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
2. 2 George, S.G., Kenny, A.J., Studies on the enzymology of purified preparations of brush border from rabbit kidney. Biochem J 134 (1973), 43–57.
3. 3 Kerr, M.A., Kenny, A.J., The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137 (1974), 477–488.
4. 4 Kerr, M.A., Kenny, A.J., The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border. Biochem J 137 (1974), 489–495.
5. 5 Malfoy, B., Sweets, J.P., Gyon, A., et al. High-affinity encephalin-degrading peptidase in mouse brain and its enhanced activity following morphine. Nature 276 (1978), 523–526.
6. 6 Roques, B.P., Fournié-Zaluski, M.C., Soroca, E., et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288 (1980), 286–288.
7. 7 Greaves, M.F., Brown, G., Rapson, N.T., et al. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 4 (1975), 67–84.
8. 8 Letarte, M., Vera, S., Tran, R., et al. Common acute lymphoblastic leukemia antigen is identical to neutral endopeptidase. J Exp Med 168 (1988), 1247–1253.
9. 9 Li, C., Chen, G., Gerard, N.P., et al. Comparison of the structure and expression of the human and rat neprilysin (endopeptidase 24.11)-encoding genes. Gene 164 (1995), 363–366.
10. 10 Tiraboschi, G., Jullian, N., Thery, V., et al. A three-dimensional construction of the active site (region 507–749) of human neutral endopeptidase (EC.3.4.24.11). Protein Eng 12 (1999), 141–149.
11. 11 D'Adamio, L., Shipp, M.A., Masteller, E.I., et al. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc Natl Acad Sci U S A 86 (1989), 7103–7107.
12. 12 Beaumont, A., Le Moual, H., Boileau, G., et al. Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (E C 3.4.24.11). J Biol Chem 266 (1991), 214–220.
13. 13 Oefner, C., D'Arcy, A., Hennig, M., et al. Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. J Mol Biol 296 (2000), 341–349.
14. 14 Pankow, K., Schwiebs, A., Becker, M., et al. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol 393 (2009), 496–503.
15. 15 Erdös, E.G., Skidgel, R.A., Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3 (1989), 145–151.
16. 16 Roques, B.P., Noble, F., Daugé, V., et al. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45 (1993), 87–146.
17. 17 Spillantini, M.G., Sicuteri, F., Salmon, S., et al. Characterization of endopeptidase 3.4.24.11 (“enkephalinase”) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol 39 (1990), 1353–1356.
18. 18 Yandle, T., Richards, M., Smith, M., et al. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 38 (1992), 1785–1791.
19. 19 Johnson, A.R., Coalson, J.J., Ashton, J., et al. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme. Am Rev Respir Dis 132 (1985), 1262–1267.
20. 20 Ronco, P., Pollard, H., Galceran, M., et al. Distribution of enkephalinase (membrane metalloendopeptidase, E.C. 3.4.24.11) in rat organs. Detection using a monoclonal antibody. Lab Invest 58 (1988), 210–217.
21. 21 Mapp, P.I., Walsh, D.A., Kidd, B.L., et al. Localization of the enzyme neutral endopeptidase to the human synovium. J Rheumatol 19 (1992), 1838–1844.
22. 22 Bowes, M.A., Kenny, A.J., Endopeptidase-24.11 in pig lymph nodes. Purification and immunocytochemical localization in reticular cells. Biochem J 236 (1986), 801–810.
23. 23 Connelly, J.C., Skidgel, R.A., Schultz, W.W., et al. Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide. Proc Natl Acad Sci U S A 82 (1985), 8737–8741.
24. 24 Kokkonen, J.O., Kuoppala, A., Saarinen, J., et al. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M–like activity and bradykinin by neutral endopeptidase. Circulation 99 (1999), 1984–1990.
25. 25 Borson, D.B., Roles of neutral endopeptidase in airways. Am J Physiol 260 (1991), L212–L225.
26. 26 Johnson, A.R., Ashton, J., Schulz, W.W., et al. Neutral metalloendopeptidase in human lung tissue and cultured cells. Am Rev Respir Dis 132 (1985), 564–568.
27. 27 Nadel, J.A., Borson, D.B., Modulation of neurogenic inflammation by neutral endopeptidase. Am Rev Respir Dis 143 (1991), S33–S36.
28. 28 Relton, J.M., Gee, N.S., Matsas, R., et al. Purification of endopeptidase 24.11 (‘enkephalinase’) from pig brain by immunoabsorbent chromatography. Biochem J 215 (1983), 519–523.
29. 29 Trejdosiewicz, L.K., Malizia, G., Oakes, J., et al. Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease. J Clin Pathol 38 (1985), 1002–1006.
30. 30 Schwartz, J.C., Costentin, J., Lecomte, J.M., Pharmacology of enkephalinase inhibitors. Trends Pharmacol Sci 6 (1985), 472–476.
31. 31 Erdös, E.G., Schulz, W.W., Gafford, J.T., et al. Neutral metalloendopeptidase in human male genital tract. Comparison to angiotensin I-converting enzyme. Lab Invest 52 (1985), 437–447.
32. 32 Bosler, J.S., Davies, K.P., Neal-Perry, G.S., Peptides in seminal fluid and their role in infertility: a potential role for opiorphin inhibition of neutral endopeptidase activity as a clinically relevant modulator of sperm motility: a review. Reprod Sci 21 (2014), 1334–1340.
33. 33 Information on EC 3.4.24.11—neprilysin. BRENDA: The Comprehensive Enzyme Information System. Available at: http://www.brenda-enzymes.org/enzyme.php?ecno=3.4.24.11. Accessed May 31, 2016.
34. 34 Potter, L.R., Natriuretic peptide metabolism, clearance and degradation. FEBS J 278 (2011), 1808–1817.
35. 35 Charles, C.J., Espiner, E.A., Nicholls, M.G., et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 271 (1996), R373–R380.
36. 36 Stephenson, S.L., Kenny, A.J., The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 243 (1987), 183–187.
37. 37 Yandle, T.G., Brennan, S.O., Espiner, E.A., et al. Endopeptidase-24.11 in human plasma degrades atrial natriuretic factor (ANF) to ANF (99-105/106-126). Peptides 10 (1989), 891–894.
38. 38 Lafferty, H.M., Gunning, M., Silva, P., et al. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res 65 (1989), 640–646.
39. 39 Kenny, A.J., Bourne, A., Ingram, J., Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 291 (1993), 83–88.
40. 40 Smith, M.W., Espiner, E.A., Yandle, T.G., et al. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 167 (2000), 239–246.
41. 41 Vodovar, N., Séronde, M.F., Laribi, S., et al., GREAT Network. High plasma B-type natriuretic peptide concentrations directly inhibit circulating neutral endopeptidase activity in heart failure. J Am Coll Cardiol HF 3 (2015), 629–636.
42. 42 Belenky, A., Smith, A., Zhang, B., et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 340 (2004), 163–172.
43. 43 Jaffe, A.S., Apple, F.S., Mebazaa, A., et al. Unraveling N-terminal pro-B-type natriuretic peptide: another piece to the very complex puzzle in heart failure patients. Clin Chem 61 (2015), 1016–1018.
44. 44 Charles, C.J., Espiner, E.A., Cameron, V.A., et al. Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep. Hypertension 17 (1991), 643–651.
45. 45 Rademaker, M.T., Charles, C.J., Espiner, E.A., et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci 91 (1996), 283–291.
46. 46 Cavero, P.G., Margulies, K.B., Winaver, J., et al. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 82 (1990), 196–201.
47. 47 Richards, A.M., Espiner, E.A., Frampton, C., et al. Inhibition of endopeptidase EC24.11 in humans. Renal and endocrine effects. Hypertension 16 (1990), 269–276.
48. 48 Richards, A.M., Crozier, I.G., Espiner, E.A., et al. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol 20 (1992), 735–741.
49. 49 Richards, A.M., Wittert, G.A., Crozier, I.G., et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced activity of atrial natriuretic peptide and angiotensin II. J Hypertens 11 (1993), 407–416.
50. 50 Richards, A.M., Crozier, I.G., Espiner, E.A., et al. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 22 (1993), 231–236.
51. 51 Florkowski, C.M., Richards, A.M., Espiner, E.A., et al. Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition. Clin Sci 92 (1997), 255–260.
52. 52 Lainchbury, J.G., Richards, A.M., Nicholls, M.G., et al. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrinol Metab 84 (1999), 723–729.
53. 53 Northridge, D.B., Jardine, A.G., Alabaster, C.T., et al. Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 2 (1989), 591–593.
54. 54 Kromer, E.P., Elsner, D., Kahles, H.W., et al. Effects of atriopeptidase inhibitor UK 79300 on left ventricular hydraulic load in patients with congestive heart failure. Am J Hypertens 4 (1991), 460–463.
55. 55 Munzel, T., Kure, S., Holtz, J., et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 86 (1992), 1089–1098.
56. 56 Richards, A.M., Wittert, G., Espiner, E.A., et al. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 71 (1992), 1501–1507.
57. 57 Rice, G.I., Thomas, D.A., Grant, P.J., et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383 (2004), 45–51.
58. 58 Lainchbury, J.G., Nicholls, M.G., Espiner, E.A., et al. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci (Lond) 95 (1998), 547–555.
59. 59 Cruden, N.L., Fox, K.A., Ludlam, C.A., et al. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 44 (2004), 913–918.
60. 60 Murphy, L.J., Corder, R., Mallet, A.I., et al. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1. Br J Pharmacol 113 (1994), 137–142.
61. 61 Abassi, Z.A., Golomb, E., Bridenbaugh, R., et al. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 109 (1993), 1024–1028.
62. 62 Vijayaraghavan, J., Scicli, A.G., Carretero, O.A., et al. The hydrolysis of endothelins by neutral endopeptidase 24.11(enkephalinase). J Biol Chem 265 (1990), 14150–14155.
63. 63 Abassi, Z.A., Tate, J.E., Golomb, E., et al. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 20 (1992), 89–95.
64. 64 Lisy, O., Joiugasaki, M., Schirger, J.A., et al. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 275 (1998), F410–F414.
65. 65 Rademaker, M.T., Charles, C.J., Cooper, G.J.S., et al. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension 39 (2002), 93–98.
66. 66 Dalzell, J.R., Seed, A., Berry, C., et al. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther 32 (2014), 13–18.
67. 67 Nathisuwan, S., Talbert, R.L., A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy 22 (2002), 27–42.
68. 68 Troughton, R.W., Rademaker, M.T., Powell, J.D., et al. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension 36 (2000), 523–530.
69. 69 McClean, D.R., Ikram, H., Garlick, A.H., et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 36 (2000), 479–486.
70. 70 Rouleau, J.L., Pfeffer, M.A., Stewart, D.J., et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. [published correction appears in Lancet 2000;356:1774] Lancet 356 (2000), 615–620.
71. 71 Packer, M., Califf, R.M., Konstam, M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002), 920–926.
72. 72 Messerli, F.H., Nussberger, J., Vasopeptidase inhibition and angio-oedema. Lancet 356 (2000), 608–609.
73. 73 Blais, C. Jr., Fortin, D., Rouleau, J.L., et al. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther 295 (2000), 621–626.
74. 74 Packer, M., McMurray, J.J.V., Desai, A.S., et al., PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
75. 75 Solomon, S.D., Zile, M., Pieske, B., et al., Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
76. 76 Vodovar, N., Paquet, C., Mebazaa, A., et al. Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. Eur Heart J 14:36 (2015), 902–905.
77. 77 Grimm, M.O., Mett, J., Stahlmann, C.P., et al. Neprilysin and Aβ clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer's disease. Front Aging Neurosci, 5, 2013, 98.
78. 78 Eckman, E.A., Adams, S.K., Troendle, F.J., et al. Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 41 (2006), 30471–30478.
79. 79 Madani, R., Poirier, R., Wolfer, D.P., et al. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 84 (2006), 1871–1878.
80. 80 Iwata, N., Tsubuki, S., Takaki, Y., et al. Metabolic regulation of brain Aβ by neprilysin. Science 292 (2001), 1550–1552.
81. 81 Meilandt, W.J., Cisse, M., Ho, K., et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 29 (2009), 1977–1986.
82. 82 Wang, H.Z., Bi, R., Zhang, D.F., et al. Neprilysin confers genetic susceptibility to Alzheimer's disease in Han Chinese. Mol Neurobiol, 2015 Sep 11 [E-pub ahead of print].
83. 83 Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.
84. 84 Webster, C.I., Burrell, M., Olsson, L.L., et al. Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease. PLoS One, 9, 2014, e104001.
85. 85 Maa, J., Grady, E.F., Yoshimi, S.K., et al. Substance P is a determinant of lethality in diet-induced hemorrhagic pancreatitis in mice. Surgery 128 (2000), 232–239.
86. 86 Kirkwood, K.S., Bunnett, N.W., Maa, J., et al. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am J Physiol Gastrointest Liver Physiol 281 (2001), G544–G551.
87. 87 Lecomte, J.M., Costentin, J., Vlaiculescu, A., et al. Pharmacological properties of acetorphan, a parenterally active “enkephalionase” inhibitor. J Pharmacol Exp Ther 237 (1986), 937–944.
88. 88 Bayes-Genis, A., Prickett, T.C., Richards, A.M., et al. Soluble neprilysin retains catalytic activity in heart failure. J Heart Lung Transplant 35 (2016), 684–685.
89. 89 Bayés-Genís, A., Neprilysin in heart failure: from oblivion to center stage. J Am Coll Cardiol HF 3 (2015), 637–640.
90. 90 Bayés-Genís, A., Barallat, J., Galán, A., et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 65 (2015), 657–665.
91. 91 Bayés-Genís, A., Barallat, J., Galán, A., et al. Multimarker strategy for heart failure prognostication. Value of neurohormonal biomarkers: neprilysin vs NT-proBNP. Rev Esp Cardiol (Engl Ed) 68 (2015), 1075–1084.
92. 92 Goliasch, G., Pavo, N., Zotter-Tufaro, C., et al. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail 18 (2016), 89–93.
93. 93 Bayés-Genís, A., Barallat, J., Pascual-Figal, D., et al. Prognostic value and kinetics of soluble neprilysin in acute heart failure. A pilot study. J Am Coll Cardiol HF 3 (2015), 641–644.
94. 94 Seronde, M.F., Mebazaa, A., Neprilysin: biotarget and biomarker in heart failure. J Am Coll Cardiol HF 3 (2015), 645–646.
95. 95 Elghetany, M.T., Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis 28 (2002), 260–274.
96. 96 Lippi, G., Banfi, G., Church, S., et al. Pre-analytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med 53 (2015), 357–370.
97. 97 Turner, A.J., Tanzawa, K., Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11 (1997), 355–364.
98. 98 Ikeda, K., Emoto, N., Raharjo, S.B., et al. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 274 (1999), 32469–32477.
99. 99 Farrah, T., Deutsch, E.W., Omenn, G.S., et al. A high-confidence human plasma proteome reference set with estimated concentrations in Peptide Atlas. Mol Cell Proteomics, 10, 2011 M110.006353.